TABLE 1

Baseline and postintervention characteristics of research participants with type 2 diabetes

BaselinePostinterventionP
n1010
Age (years)44 ± 3
BMI (kg/m2)34.0 ± 0.731.9 ± 0.7<0.001
Weight (kg)99.5 ± 3.892.4 ± 3.4<0.001
Fat mass (kg)36.6 ± 2.131.1 ± 2.1<0.001
Lean body mass (kg)60.0 ± 4.159.1 ± 3.7
Visceral fat (cm2)242.0 ± 28.0183.0 ± 17.0<0.01
Subcutaneous abdominal fat (cm2)382.0 ± 31.0360.0 ± 30.0
Subcutaneous midthigh fat (cm2)108.0 ± 19.0101.0 ± 21.0
Intermyofascial midthigh fat (cm2)16.0 ± 3.012.0 ± 1.0
Thigh muscle CT attenuation (HU)48.2 ± 1.050.3 ± 0.9<0.01
Liver-to-spleen CT attenuation ratio0.83 ± 0.091.11 ± 0.06<0.01
Vo2max (ml O2 · min−1 · kg lbm−1)43.5 ± 1.648.6 ± 1.6<0.001
Maximal METs8.7 ± 0.512.0 ± 0.5<0.001
A1C (%)7.85 ± 0.526.47 ± 0.25<0.01
Oral glucose tolerance test (75g)
    Glucose, 0 min (mg/dl)164.0 ± 15.0126.0 ± 6.0<0.05
    Glucose, 120 min (mg/dl)260.0 ± 16.0205.0 ± 15.0<0.01
  • Data are means ± SEM unless otherwise indicated. CT, computed tomography; lbm, lean body mass.